The top 10 PharmTech videos of the year cover advanced therapies, high-concentration biologics, major mergers and ...
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...
All in all, PHAT has 6 recent analyst reviews that break down into 5 Buys and 1 Hold, giving the stock a Strong Buy consensus rating. The shares are priced at $17.66 and have an average price target ...
Findings from two clinical trials suggest Novartis' Itvisma is safe and effective for SMA patients over 2 years old.
Zacks Investment Research on MSN
RARE rises on completion of rolling submission for AAV gene therapy
Shares of Ultragenyx Pharmaceutical RARE were up 15.5% yesterday following the completion of the rolling submission of a ...
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), ...
Ultragenyx (RARE) announced that it has completed the rolling submission of its biologics license application to the FDA, seeking approval for ...
X-linked retinoschisis gene replacement therapy, aiming to improve retinal architecture and visual function in young male ...
A small group of volunteers will receive multiple injections of the experimental treatments next month, says Unlimited Bio.
News-Medical.Net on MSN
Advances in hemophilia gene therapy bring hope for pediatric patients
In the past three years, gene therapy has reshaped what's possible in hemophilia treatment for patients 18 and older. But a ...
Revolutions in gene therapy are rapidly changing the landscape of modern medicine. Revolutions in gene therapy are rapidly changing the landscape of modern medicine, forcing society and science alike ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback